Related Experiment Video

Updated: Jan 16, 2026

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
08:33

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

1.6K

WASOG Clinical Trial Endpoint Task Force: Executive Summary

Robert P Baughman1, Elyse E Lower2, Daniel A Culver3

  • 1Editor-in-chief, Sarcoidosis, Vasculitis and Diffuse Lung Diseases; University of Cincinnati, Department of Medicine, Cincinnati, OH, USA.

Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG
|September 30, 2025
PubMed

Insights

New guidelines address clinical trial endpoints for pulmonary and cardiac sarcoidosis. The World Association of Sarcoidosis and Other Granulomatous disease (WASOG) Task Force developed thirteen endorsed statements for future research.

Area of Science:

  • Pulmonology
  • Cardiology
  • Rheumatology
  • Clinical Trials

Background:

  • Clinical trials for pulmonary and cardiac sarcoidosis lack standardized endpoints.
  • Previous World Association of Sarcoidosis and Other Granulomatous disease (WASOG) guidelines were established in 2011.
  • There is a growing need for updated consensus on trial endpoints.

Purpose of the Study:

  • To update the 2011 WASOG clinical trial endpoint guidelines.
  • To establish consensus on appropriate endpoints for pulmonary and cardiac sarcoidosis clinical trials.
  • To reflect the latest advancements and expert opinions in sarcoidosis research.

Main Methods:

  • Formation of a WASOG clinical trial endpoint Task Force in 2024.
  • Involved 55 stakeholders: healthcare providers, industry representatives, and patients.
  • A one-day meeting with 46 participants and twenty focused talks on trial endpoints.
  • Compilation of summaries, feedback collection, and anonymous voting on developed statements.

Main Results:

  • Thirteen specific clinical trial endpoint statements were endorsed by a majority of stakeholders.
  • Two statements focused on overall trial design.
  • Seven statements addressed pulmonary sarcoidosis endpoints.
  • Four statements focused on cardiac sarcoidosis endpoints.

Conclusions:

  • The updated WASOG guidelines provide a consensus on crucial clinical trial endpoints for sarcoidosis.
  • These endpoints will help standardize future research in pulmonary and cardiac sarcoidosis.
  • The endorsed statements aim to improve the design and comparability of clinical trials.

More Related Videos

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.1K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.5K

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.1K
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
144
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
227
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
407
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.3K